Polymorphism and crystallisation are considered to be one of the most significant and demanding areas of pharmaceutical development. New discoveries have the potential to either give organisations a share of a crowded market place to great financial and reputational benefit or have hugely damaging repercussions, depending on at what stage the alternative crystallisation formation was discovered.
However, with the swift leaps and bounds in technology development and quality by design processes, organisations are also faced with the challenge of keeping up to date with the latest research in order to stay at the forefront of the industry, as well as improve safety, best practice and the efficacy of drugs.
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |